Executive Officers

Paul V. Campanelli

Paul V. Campanelli is President, Chief Executive Officer and a Director of Endo International plc. Mr. Campanelli joined Endo in 2015 as the President of Par Pharmaceutical, leading Endo’s fully integrated U.S. Generics business, following Endo’s acquisition of Par Pharmaceutical. Prior to joining Endo, he had served as Chief Executive Officer of Par Pharmaceutical Companies, Inc. following the company’s September 2012 acquisition by TPG. While CEO of Par, Mr. Campanelli built a strong leadership team and an industry-leading generics business. Under his leadership, the company significantly increased total revenue, acquired Michigan-based JHP Pharmaceuticals, established a business office in London to serve as Par’s entry point into the European generics market and completed its acquisition of an active pharmaceutical ingredients (API) facility located in Chennai, India. Prior to the TPG acquisition, Mr. Campanelli served as Chief Operating Officer and President of Par Pharmaceutical, Inc., the company’s generics division, from 2011 to 2012.  Earlier in his tenure at Par, Mr. Campanelli held roles of increasing responsibility, including Senior Vice President, Business Development & Licensing; Executive Vice President and President of Par Pharmaceutical, Inc.; and was named a Corporate Officer by Par’s board of directors. He also served on the board of directors of Sky Growth Holdings Corporation.  Prior to joining Par, Mr. Campanelli served as Vice President, Business Development at Dr. Reddy’s Laboratories Ltd. where he was employed from 1992-2001. Mr. Campanelli earned his Bachelor of Science degree from Springfield College.   

Joseph J. Ciaffoni 

Joseph J. Ciaffoni joined Endo as President, U.S. Branded Pharmaceuticals in August 2016. In his role, Mr. Ciaffoni leads Endo’s U.S. Branded Pharmaceutical business, driving the development and execution of Endo’s branded strategy and accelerating key growth drivers. His extensive industry experience includes building commercial businesses, leading multi-function organizations and achieving significant results across primary care, specialty and rare disease markets. Prior to joining Endo, Mr. Ciaffoni served as Senior Vice President, Global Specialty Medicines Group for Biogen where he led the development and execution of all aspects of global strategy across the value chain for marketed and pipeline products. Mr. Ciaffoni joined Biogen Idec in 2012 and during his tenure also held senior roles including Senior Vice President, U.S. Commercial and Vice President, U.S. Neurology Field Operations and Marketing. Prior to joining Biogen, Mr. Ciaffoni was Executive Vice President and Chief Operating Officer of Shionogi Inc. and President of Shionogi Pharmaceuticals. Previously, he served as Vice President, Sales for Schering-Plough (now Merck) and held several commercial leadership roles at Sanofi-Synthelabo (now Sanofi) and Novartis. Mr. Ciaffoni holds a B.A. in Communications and an M.B.A. from Rutgers, The State University of New Jersey. 

Blaise Coleman

Blaise Coleman, Senior Vice President Global Finance Operations, was appointed Interim Chief Financial Officer effective November 22, 2016. Mr. Coleman joined Endo in January 2015 as Vice President of Corporate Financial Planning & Analysis and was promoted to Senior Vice President of Global Finance Operations in November 2015. Prior to joining Endo, Mr. Coleman held a number of finance leadership roles with AstraZeneca, a global biopharmaceutical company, latterly as the Chief Financial Officer of the AstraZeneca/Bristol-Myers Squibb US Diabetes Alliance from January 2013 until January 2015. Prior to this, he was the Head of Finance for the AstraZeneca Global Medicines Development organization based in Mölndal, Sweden from September 2011 to January 2013. Mr. Coleman joined AstraZeneca as Senior Director Commercial Finance for the US Cardiovascular Business in November 2007. He joined AstraZeneca from Centocor, a wholly owned subsidiary of Johnson & Johnson, where he held positions in the respective Licenses & Acquisitions and Commercial Finance organizations. Mr. Coleman’s move to Centocor in early 2003 followed 7 years’ experience with the global public accounting firm, PricewaterhouseCoopers LLP. He is a Certified Public Accountant. Mr. Coleman received a Bachelor of Science in accounting from Widener University and a MBA from Duke University, The Fuqua School of Business.  

Terrance J. Coughlin

Terrance J. Coughlin was appointed Executive Vice President and Chief Operating Officer effective November 1, 2016. In this role, Mr. Coughlin has responsibility for Manufacturing and Technical Operations, as well as Endo Ventures and R&D across the enterprise. Most recently, Mr. Coughlin served as Vice President, Operations of Par Pharmaceutical Companies, Inc., a subsidiary of Endo. Prior to Endo’s acquisition of Par in September 2015, Mr. Coughlin was the Chief Operating Officer of Par Pharmaceutical Companies, Inc. Prior to joining Par, Mr. Coughlin held a number of leadership roles with Glenmark Generics, Inc. USA/Glenmark Generics Limited latterly as the President and Chief Executive Officer of Glenmark Generics, Inc. USA/Glenmark Generics Limited. Prior to this, Mr. Coughlin had the overall responsibility for Glenmark’s North American, Western European and Eastern European generics businesses, as well as its global active pharmaceutical ingredient business and generics operations in India. Prior to joining Glenmark, Mr. Coughlin served as Senior Vice President at Dr. Reddy’s Laboratories, Inc. Mr. Coughlin began his career in 1988 with Wyckoff Chemical Company, Inc. Mr. Coughlin earned a B.S. in chemistry from Central Michigan University.

Matthew J. Maletta

Matthew J. Maletta was appointed Executive Vice President, Chief Legal Officer effective May 4, 2015. He has 20 years of legal experience in the specialty pharmaceutical industry and with private law firms, including extensive experience in M&A, corporate, securities, finance, commercial and employment law. Prior to joining Endo, Mr. Maletta served as Vice President, Associate General Counsel and Corporate Secretary of Allergan, Inc. In this position, he served as an advisor to the CEO and Board of Directors and supervised several large M&A transactions and takeover defense activities, including Allergan’s acquisition of Inamed and Actavis’ acquisition of Allergan. Mr. Maletta first joined Allergan in 2002 as Corporate Counsel and Assistant Secretary and during his tenure, held various roles of increased responsibility. He had a key role negotiating Allergan’s Corporate Integrity Agreement with the Department of Justice, served as the lead commercial attorney for the Allergan medical businesses and served as Interim Head of Human Resources. Prior to joining Allergan, Mr. Maletta was in private practice, focusing on general corporate matters, finance, governance, securities and transactions. He holds a B.A. degree in political science from the University of Minnesota, summa cum laude, and a J.D. degree, cum laude, from the University of Minnesota Law School. From 2012 – 2015, Mr. Maletta served as a member of the Board of Directors of United Cerebral Palsy – Orange County (UCP) and co-chaired UCP’s annual “Life Without Limits” galas in 2012, 2013 and 2015.

Dan A. Rudio

Daniel A. Rudio was appointed Vice President, Controller and Chief Accounting Officer effective April 1, 2011. Mr. Rudio joined Endo in November 2006 as Financial Reporting Manager and has held various positions of increasing responsibility. Prior to joining the Company, Mr. Rudio was a finance manager at Rohm and Haas Company where he worked for four years in a variety of accounting and finance positions of increasing responsibility. Mr. Rudio began his career in public accounting at Ernst & Young LLP where he worked from July 1995 to November 2002. Mr. Rudio is a licensed certified public accountant in the Commonwealth of Pennsylvania and holds Bachelors of Science degrees in both accounting and finance from Rutgers University.


Senior Management 

Joseph A. Barbarite

Joseph A. Barbarite is Executive Vice President, Global Quality and Compliance effective November 2016. He joined Endo in 2015 as the Senior Vice President, Global Quality and Compliance for Par Pharmaceutical, following Endo’s acquisition of Par. Mr. Barbarite brings over 35 years of pharmaceutical quality and compliance experience covering both generic and branded organizations.  Prior to joining Par in 2004, he held leadership roles in Commercial and Pre-Commercial Quality at Forest Research Institute and Forest Laboratories, Inc. Prior to Forest Laboratories, he held management positions at Nycomed Inc. and at Sterling Winthrop Inc. Earlier in his career, Mr. Barbarite held QA auditing positions at Organon, Inc. and Altana, Inc. He started his career at Nice-Pak Products Inc. as the Quality Assurance Supervisor. Mr. Barbarite holds a Bachelor of Science in Biology from Fordham University as well as a Quality Engineer certification from the American Society for Quality. 

Mark Bradley

Mark Bradley serves as Senior Vice President, Corporate Development. Mr. Bradley joined Endo in January 2007 as a Finance Director and has held various positions of increasing responsibility since joining the company. Prior to joining Endo, he spent nearly 7 years as a management consultant, most recently with Deloitte Consulting, providing a broad range of strategic and operational advice and services to senior executives across a number of industries. In addition, Mr. Bradley served as a Finance Director for an industrial products company for approximately 2 years. He spent the first 5 years of his career in public accounting at Ernst & Young LLP and received his CPA in October 1993. Mr. Bradley holds a Bachelor of Science degree in Accounting from Saint Joseph’s University and a Master of Business Administration from The University of Texas at Austin. 

Larry Cunningham

Larry Cunningham, Executive Vice President, Human Resources, joined Endo in May 2008. In this role he leads all aspects of human resources in enabling the development and growth of Endo. Prior to joining Endo, Mr. Cunningham led Johnson & Johnson’s global recruiting and talent acquisition organization. Mr. Cunningham also has extensive business-based human resources leadership experience. He was Vice President, Human Resources, for DePuy, Inc., a wholly owned subsidiary of Johnson & Johnson, which he joined following the acquisition of Centocor, where he was Vice President, Human Resources. Prior to joining Centocor, Mr. Cunningham gained extensive domestic and international experience in human resources management and organization development at Rhone-Poulenc Rorer (now Sanofi-Aventis) and Corning Clinical Laboratories (now Quest Diagnostics). Mr. Cunningham holds a B.A. in Labor Studies from the Pennsylvania State University and a Master of Science in Business Administration from Temple University.

Jennifer E. Dubas

Jennifer E. Dubas is Senior Vice President and Chief Compliance Officer, effective October 2016. In this role, she is responsible for the strategic direction and operations of Endo’s corporate compliance program. Ms. Dubas joined Endo in 2011 and has been a valued member of Endo’s Legal leadership team, previously serving as Endo’s Senior Vice President, Associate General Counsel where she was responsible for managing all non-IP, non-employment litigation for Endo and its subsidiaries. In 2015, she accepted the additional responsibility of managing the legal support for Endo’s U.S. Branded Pharmaceutical business. In this role, in addition to advising the business on legal matters, Ms. Dubas also provided legal support to Endo’s Compliance organization, including the advising on the successful management of Endo’s 2014 Corporate Integrity Agreement (CIA) and Deferred Prosecution Agreement (DPA).  She has spent her 16 year legal career providing effective advice to pharmaceutical, medical device and consumer products companies. Ms. Dubas began her professional career as an associate in Dechert’s litigation group where she represented various pharmaceutical and consumer product companies. In 2005, Ms. Dubas joined Wyeth’s in-house litigation team and then served in a similar capacity for Pfizer, following its acquisition of Wyeth. She holds a Juris Doctor degree, magna cum laude, from Temple University, and a Bachelor of Arts degree, magna cum laude, from Bryn Mawr College.   

Rahul Garella

Rahul Garella was appointed Senior Vice President, Head of International Pharmaceuticals in November 2016 and has responsibility for Endo’s international businesses, including Paladin Labs, Par Laboratories Europe,Ltd,  Grupo Farmaceutico SOMAR and Litha Healthcare. Mr. Garella has 20 years’ experience in the pharmaceutical industry across APIs and finished dosages with broad international experience across the European, Asian and Latin America markets. He joined Par in November 2014 and was tasked with establishing Par Laboratories Europe Limited in the United Kingdom with responsibility for building up the commercial and regulatory infrastructure, operating team and product pipeline across generic and branded products. Prior to joining Par, Mr. Garella served as Senior Vice President for Glenmark Pharmaceuticals Europe Limited for the Western European generics business from 2008 until 2014 and European and Latin American API business from 2005 until 2008. Previously, he worked with Ranbaxy in their Asia-Pacific division and Orchid Chemicals & Pharmaceuticals. He holds a Master of Business Administration (PGDBM) from the Institute of Management Technology, India as well as a Bachelor degree in Electrical Engineering from the Faculty of Engineering, Jamia Millia, New Delhi, India. 

Stephen Mock 

Stephen Mock is Senior Vice President, Investor Relations & Corporate Affairs. In this role, he is responsible for the development and implementation of the company’s comprehensive and strategic IR and corporate communications platform as well as Government Affairs efforts. Mr. Mock brings more than 30 years of corporate and business unit experience to Endo. Most recently, he served as Senior Advisor, Business Development at Par Pharmaceutical and previously as Vice President, Corporate Affairs at Par. Prior to joining Par Pharmaceutical in 2003, Mr. Mock spent almost 20 years of his professional career at Warner-Lambert Company where he held positions of increasing responsibility in finance, investor relations and public affairs. Serving as Vice President, Public Relations, his responsibilities included media relations, marketing communications and community affairs. Mr. Mock also served on the board of the Warner-Lambert Foundation. Prior to that, as Director, Investor Relations, he served as the company’s chief spokesperson with the financial community. Mr. Mock also held positions in Consumer Health Care, as Director, Financial Planning and Analysis, Corporate Finance and Treasury. Mr. Mock earned a Bachelor of Science in Finance and a Bachelor of Arts in International Relations from Lehigh University. He also holds a Master of Business Administration from Fairleigh Dickinson University, with concentrations in Accounting and Finance.  

Tony Pera

Tony Pera was named President, Par Pharmaceutical effective November 1, 2016. In this role, Mr. Pera leads Endo’s U.S. Generics business including responsibility and oversight of Par Generic and Par Sterile sales teams, as well as Par’s marketing & business analytics group. Most recently, Mr. Pera served as Chief Commercial Officer of Par Pharmaceutical. He joined Par in February 2014 as part of Par’s acquisition of JHP Pharmaceutical, where he held a similar position. As Chief Commercial Officer, Mr. Pera was responsible for all sales, marketing, pricing and customer operations functions for Par. Prior to JHP and Par, Mr. Pera was Senior Vice President of Supply Chain Management for AmerisourceBergen (ABC), a major U.S. pharmaceutical wholesaler, for approximately five years. Prior to ABC, he held numerous senior leadership positions with generic drug companies including APP (now Fresenius Kabi), Bedford Laboratories and LyphoMed. Mr. Pera started his career as a sales representative for the parenteral products division of Baxter. He currently serves as the Secretary-Treasurer of the Board of Directors for the Generic Pharmaceutical Association (GPhA). Mr. Pera holds a B.S. in Business Administration from the University of Illinois in Champaign and an M.B.A. from DePaul University. 

Brandon Rockwell

Brandon Rockwell was appointed Vice President of Business Development in November 2016. Most recently, Mr. Rockwell served as Executive Director of Business Development at Par Pharmaceutical, a subsidiary of Endo, where he managed a cross functional department of 17 employees globally, which consisted of Business Development, Portfolio Management, Project Management and Strategic API Sourcing. Brandon joined Par Pharmaceutical in 2007 and has played an integral role in setting the strategic direction of the company through the acquisitions of Edict, Anchen, JHP and the integration of Qualitest and Par. Mr. Rockwell has 10 year of experience in the pharmaceutical industry, having held various prior positions in business development, project management and information systems. Mr. Rockwell has a Bachelor of Science from Grove City College and a Master of Business Administration from New Jersey Institute of Technology.